The vaccine and biotechnology company Abera Bioscience announces that the company is initiating additional preclinical studies in its influenza project focusing on pandemic avian influenza. The studies are conducted in well-established ferret models that are considered to have high predictivity for future efficacy in humans and are intended to provide a broader and more robust data set ahead of the next development step.The decision follows very promising preclinical results that were presented in 2025. As a result, Coalition for Epidemic Preparedness Innovations has approved an extension of the project through June 30 to enable more and broader preclinical studies during the spring, where reprioritizations have freed up budget without changing the project’s total budget.